Chinese biopharma Hutchmed has announced that the pivotal Phase III trial ESLIM-01 evaluating the investigational use of sovleplenib met its primary endpoint of 21 August 2023
Singapore-listed healthcare company Medi Lifestyle has announced a collaboration involving its subsidiaries, HealthPro Pharma and Healthpro Marketing, with FIOR 16 August 2023
US CMS specialist Corium and Taiwan-based Lotus Pharmaceutical have entered into an exclusive collaboration and license deal for Adlarity (donepezil transdermal 11 August 2023
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.